基于人血清白蛋白的药物递送系统研究进展  

Research Progress of Human Serum Albuminbased Drug Delivery Systems

作　　者：陈重 野庆松 吴锦慧[1] CHEN Zhong;YE Qingsong;WU Jinhui(Medical School,Nanjing University,Nanjing 210093,China)

机构地区：[1]南京大学医学院,江苏南京210093

出　　处：《药学进展》2022年第7期495-501,共7页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金(No.32171372,No.31872755,No.81872811);江苏省杰出青年基金(No.BK20190007)。

摘　　要：人血清白蛋白是血液中的一种天然转运蛋白,其生理功能主要是与各种内源性物质和外源性分子结合,然后转运到体内各种组织。人血清白蛋白的内部结合位点和表面活性基团使其能够同时携带多种分子进行多功能治疗。此外,在温和的条件下,人血清白蛋白还可以通过不同的方法被制备成载药纳米粒子。基于人血清白蛋白的药物递送系统因其具有生物降解性、非免疫原性、生物相容性和较长的半衰期等特点,近年来受到越来越多的关注。综述了基于人血清白蛋白的药物递送系统的最新研究进展,并提出了人血清白蛋白制剂临床转化面临的挑战和未来发展方向。Human serum albumin(HSA)is a natural transport protein in the blood.Its physiological function is mainly to combine with various endogenous substances and exogenous molecules,and then to transport them to various tissues in the body.The internal binding sites and surface-active groups of HSA enable it to carry multiple molecules simultaneously for multifunctional therapy.In addition,under mild conditions,HSA can also be used to prepare drug-loaded nanoparticles via different methods.HSA-based drug delivery systems have received increasing attention in recent years due to their biodegradability,non-immunogenicity,biocompatibility,and long half-life.This article reviews the latest research progress of HSA-based drug delivery systems,and presents the challenges and future development directions for the clinical translation of HSA preparations.

关 键 词：人血清白蛋白 纳米粒子 药物递送 白蛋白结合蛋白 

分 类 号：R94[医药卫生—药剂学]